Landmark PACK-CXL trial published
Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
Prof. Farhad Hafezi
January 12, 2022
Today, a landmark PACK-CXL trial was published that shows that PACK-CXL is an effective corneal infection therapy.
Researchers from ELZA, the ETH Zurich, the University of Zurich and the University of South Florida investigate corneal biomechanics in a mouse model for Ehlers-Danlos
Is it useful to cool the cornea during cross-linking? The researchers at ELZA are constantly trying to improve corneal cross-linking. Back in 2013, we identified
Why would you want to perform corneal cross-linking at the slit lamp? Well, it is a powerful and versatile therapy, that can not only halt
It’s clear that there is a link between eye rubbing and keratoconus. Eye rubbing can alter the strength of the cornea, which can cause keratoconus to
We at the ELZA Institute are proud to report that our landmark paper that describes how the sub400 protocol is used to perform CXL in
We took a biological approach to what has been classically viewed as a physics problem. If the laser ablation is causing inflammation, can we change how the laser energy is delivered to the cornea in order to cause less inflammation?
And so, at this year’s annual meeting of the European Society for Cataract and Refractive Surgery (ESCRS 2020), held online from 2–4 October 2020, a poster, presented by Dr. Emilio Torres-Netto, entitled “Corneal cross-linking for treating infectious keratitis: final results of the prospective randomized controlled multicentre trial” took first place in the Refractive Surgery category. The phase III trial results showed that corneal ulcers can be treated just as effectively with PACK-CXL as with the latest antibiotics, something that will soon become increasingly important.
What effect does corneal cross-linking have after 10 years? This August, ELZA doctor and researcher, Emilio Torres-Netto MD was interviewed by TouchOphthalmology on a recent congress presentation he gave on 10-year cross-linking follow-up data collated from two treatment centers in Zurich, and was asked about what the research group found.
